Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Salman Afsar

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Frontiers in Drug Safety and Regulation|September 22, 2025
Exploring the scientific underpinnings of investigating safety signals: analytical insights in deciphering drug safety evidenceTarek A Hammad, Simon Davis, Salman Afsar
Frontiers in Drug Safety and Regulation|September 22, 2025
Navigating a transforming landscape: the evolving role of pharmacovigilance physicians in drug development and implications for future challenges and training requirementsTarek A Hammad, Salman Afsar, Herve Le-Louet, et al.
Frontiers in Drug Safety and Regulation|September 22, 2025
Aspects to consider in causality assessment of safety signals: broadening the thought processTarek A Hammad, Salman Afsar, Laura B McAvoy, et al.
Reproductive Toxicology (Elmsford, N.Y.)|May 15, 2020
Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomideLily J Henson, Salman Afsar, Lynn Davenport, et al.
Drug Safety|July 15, 2026
Augmenting Medical Judgment in Signal Confirmation: Design Considerations for an AI-Enabled Causality Assessment FrameworkTarek A Hammad, Justine Rochon, Salman Afsar, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 11, 2019
Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experienceSandra Vukusic, Patricia K Coyle, Stephanie Jurgensen, et al.
International Journal of Environmental Research and Public Health|August 12, 2022
Public's Mental Health Monitoring via Sentimental Analysis of Financial Text Using Machine Learning TechniquesSaad Awadh Alanazi, Ayesha Khaliq, Fahad Ahmad, et al.
Neurology and Therapy|May 16, 2020
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS StudiesAntonio Bertolotto, Rafael Arroyo, Elisabeth G Celius, et al.
The Oncologist|April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 AnalysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist|May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Frontiers in Drug Safety and Regulation|September 22, 2025
Exploring the scientific underpinnings of investigating safety signals: analytical insights in deciphering drug safety evidenceTarek A Hammad, Simon Davis, Salman Afsar
Frontiers in Drug Safety and Regulation|September 22, 2025
Navigating a transforming landscape: the evolving role of pharmacovigilance physicians in drug development and implications for future challenges and training requirementsTarek A Hammad, Salman Afsar, Herve Le-Louet, et al.
Frontiers in Drug Safety and Regulation|September 22, 2025
Aspects to consider in causality assessment of safety signals: broadening the thought processTarek A Hammad, Salman Afsar, Laura B McAvoy, et al.
Reproductive Toxicology (Elmsford, N.Y.)|May 15, 2020
Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomideLily J Henson, Salman Afsar, Lynn Davenport, et al.
Drug Safety|July 15, 2026
Augmenting Medical Judgment in Signal Confirmation: Design Considerations for an AI-Enabled Causality Assessment FrameworkTarek A Hammad, Justine Rochon, Salman Afsar, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 11, 2019
Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experienceSandra Vukusic, Patricia K Coyle, Stephanie Jurgensen, et al.
International Journal of Environmental Research and Public Health|August 12, 2022
Public's Mental Health Monitoring via Sentimental Analysis of Financial Text Using Machine Learning TechniquesSaad Awadh Alanazi, Ayesha Khaliq, Fahad Ahmad, et al.
Neurology and Therapy|May 16, 2020
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS StudiesAntonio Bertolotto, Rafael Arroyo, Elisabeth G Celius, et al.
The Oncologist|April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 AnalysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist|May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
Pageof 1